129 related articles for article (PubMed ID: 15359148)
1. Telithromycin (Ketek) for community-acquired respiratory tract infections.
Wimett L; Laustsen G
Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
[No Abstract] [Full Text] [Related]
2. Telithromycin (Ketek) for respiratory infections.
Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
[No Abstract] [Full Text] [Related]
3. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
4. Telithromycin.
Spiers KM; Zervos MJ
Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
[TBL] [Abstract][Full Text] [Related]
5. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
6. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
8. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
Carbon C
Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
[TBL] [Abstract][Full Text] [Related]
9. Introduction: PROTEKT against respiratory tract infection.
Stratton CW
J Chemother; 2002 Jul; 14 Suppl 3():5-8. PubMed ID: 12418555
[No Abstract] [Full Text] [Related]
10. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
11. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
12. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
Clark JP; Langston E
Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
[TBL] [Abstract][Full Text] [Related]
13. [Telithromycin: a new therapeutic option for community-acquired respiratory infection].
Muñoz MJ; Azanza JR; Escolar M; Macaya A; Gil FJ
Rev Med Univ Navarra; 2002; 46(3):37-44. PubMed ID: 12685116
[No Abstract] [Full Text] [Related]
14. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
Felmingham D; Zhanel G; Hoban D
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.
Nicolau DP
Expert Opin Pharmacother; 2004 Feb; 5(2):229-35. PubMed ID: 14996620
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
17. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of ketoride antibiotics, telithromycin in treatment of respiratory tract infections (discussion)].
Kohno S; Watanabe A; Aoki N; Niki Y
Jpn J Antibiot; 2003 Dec; 56(6):531-45. PubMed ID: 15007871
[No Abstract] [Full Text] [Related]
19. [Telithromycin, a once-a-day ketolide in the treatment of community acquired pneumonia].
Carbon C
Presse Med; 2000 Dec; 29(37):2042-3. PubMed ID: 11155730
[TBL] [Abstract][Full Text] [Related]
20. [Telithromycin].
Benes J
Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
